NEW YORK (GenomeWeb News) – Molecular diagnostic firm Linkage Biosciences today announced it raised $2 million in growth capital.

The company did not specify how the funds will be used, but CEO Zachary Antovich noted growing demand for the firm's LinkSeq products and said in a statement that the funds will "help accelerate our efforts around the world."

Fisher Capital led the round. All existing investors, including Greenhouse Capital Partners and Big Sky Partners, also participated, Linkage Bio said

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.